PLX stock news

PLX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-29 18:42:01 UTC#539897newconfirmednews

Plexus forecasts mid- to upper teens FY2027 revenue growth and sets 6.5%-7% non-GAAP operating margin target

seeking alphaimportance 0.50trust 0.70Plexus Corp. +0.40

2026-10-29 14:24:43 UTC#538165newconfirmednews

Plexus reports FY26 revenue of $5B, forecasts mid- to upper-teens revenue growth for FY27

quartrimportance 0.50trust 0.70Plexus Corp. +0.60

2026-10-29 12:27:08 UTC#537200newconfirmednews

Plexus Corp. Q4 2026 earnings call begins

tradingviewimportance 0.30trust 0.70Plexus Corp. 0

2026-10-28 21:19:42 UTC#532708newconfirmeddata release

Plexus Q3 Non-GAAP EPS $2.84 beats by $0.29, Revenue $1.43B beats by $70M

seeking alphaimportance 0.50trust 0.90Plexus Corp. +0.60

2026-10-28 20:55:02 UTC#532511duplicateconfirmedpress release

Plexus Corp. reports fiscal fourth quarter and full year 2026 financial results

reutersimportance 0.30trust 0.90Plexus Corp. 0

2026-10-28 20:19:14 UTC#532301newconfirmedpress release

Plexus Corp. reports fiscal Q4 2026 revenue of $1.427 billion and 6.0% GAAP operating margin

financial postimportance 0.60trust 1.00Plexus Corp. 0

2026-10-26 21:24:06 UTC#517496newforecastnews

Plexus Corp Q3 2026 earnings preview: analysts expect $2.56 EPS and $1.359B revenue

reutersimportance 0.40trust 0.80Plexus Corp. 0London Stock Exchange Group plc 0

2026-10-14 20:15:00 UTC#461585newconfirmedpress release

Plexus Corp. to report fiscal Q4 and full-year 2026 results on October 28, 2026

globenewswireimportance 0.30trust 1.00Plexus Corp. 0

2026-09-22 13:44:53 UTC#349294duplicateconfirmednews

Wall Street analyst roundup: Brinker, MetLife, and Plexus upgraded; Netflix and SanDisk coverage noted

yahooimportance 0.30trust 0.70Netflix, Inc. -0.30SanDisk Corporation +0.30Brinker International, Inc. +0.40+2 entities

2026-09-22 10:15:12 UTC#347749newconfirmednews

KeyBanc upgrades Plexus Corp to Overweight, sets $300 price target citing strong growth prospects

tradingviewimportance 0.40trust 0.70Plexus Corp. +0.60KeyBanc Capital Markets Inc. +0.60

2026-08-24 20:57:00 UTC#214336duplicateconfirmednews

Plexus Corp. authorizes new $100 million share repurchase program

dow_jonesimportance 0.30trust 0.90Plexus Corp. +0.30U.S. Securities and Exchange Commission 0

2026-08-24 20:23:03 UTC#214191duplicateconfirmednews

Plexus Corp. authorizes new $100 million share repurchase program

tradingviewimportance 0.30trust 0.80Plexus Corp. +0.30

2026-08-24 20:19:00 UTC#214156newconfirmednews

Plexus Corp. (PLXS) authorizes new $100 million common stock repurchase program

dow_jonesimportance 0.40trust 0.90Plexus Corp. +0.30

2026-08-14 17:32:00 UTC#179437newconfirmednews

Needham maintains $310.00 price target on Plexus Corp. (PLXS)

dow_jonesimportance 0.30trust 0.70Plexus Corp. 0Needham & Company, LLC 0

2026-08-12 17:58:09 UTC#166946newconfirmednews

Protalix targets 15-20% Fabry market share for Elfabrio by 2031 following European approval

seeking alphaimportance 0.50trust 0.70Protalix BioTherapeutics, Inc. +0.50Elfabrio +0.60

2026-08-12 13:47:32 UTC#165572duplicateconfirmednews

Protalix BioTherapeutics Q2 2026 net income reaches $3.8M on Elfabrio sales and milestone payments

quartrimportance 0.30trust 0.60Protalix BioTherapeutics, Inc. +0.50Elfabrio +0.50PRX-115 +0.30

2026-08-12 11:23:35 UTC#164655duplicateconfirmednews

Protalix BioTherapeutics reports H1 2026 net income of $22.1M on doubled revenue, boosted by $25M Chiesi milestone

quartrimportance 0.30trust 0.70Protalix BioTherapeutics, Inc. +0.60Chiesi Farmaceutici S.p.A. +0.50

2026-08-12 11:03:28 UTC#164547updateconfirmednews

Protalix BioTherapeutics reports strong 2026 revenue and profitability, reaffirms full-year guidance

quartrimportance 0.40trust 0.70Protalix BioTherapeutics, Inc. +0.50Elfabrio +0.50

2026-08-12 11:03:12 UTC#164559duplicateconfirmednews

Protalix BioTherapeutics reports H1 2026 revenue of $53.6M and net income of $22.1M

tradingviewimportance 0.30trust 0.80Protalix BioTherapeutics, Inc. +0.40

2026-08-12 11:02:01 UTC#164570duplicateconfirmednews

Protalix BioTherapeutics Q2 net income rises to $3.8M on Elfabrio sales, reiterates 2026 revenue guidance

reutersimportance 0.30trust 0.90Protalix BioTherapeutics, Inc. +0.50Chiesi Farmaceutici S.p.A. +0.40Fundação Oswaldo Cruz +0.30+2 entities